AIM ImmunoTech Files 8-K on Shareholder Vote Matters
Ticker: AIM · Form: 8-K · Filed: Dec 20, 2024 · CIK: 946644
| Field | Detail |
|---|---|
| Company | Aim Immunotech INC. (AIM) |
| Form Type | 8-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, filing
TL;DR
AIM ImmunoTech held a shareholder vote on Dec 17; 8-K filed Dec 20.
AI Summary
AIM ImmunoTech Inc. filed an 8-K on December 20, 2024, reporting on matters submitted to a vote of its security holders on December 17, 2024. The filing details the company's operations in biological products, specifically excluding diagnostic substances, and its principal executive offices are located in Ocala, Florida.
Why It Matters
This filing indicates a formal process of shareholder engagement on significant company decisions, which can impact corporate governance and future strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain information about significant financial changes, legal issues, or operational disruptions.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- December 17, 2024 (date) — Date of earliest event reported
- December 20, 2024 (date) — Date of report
- Ocala, FL (location) — Principal executive offices
- HEMISPHERX BIOPHARMA INC (company) — Former company name
FAQ
What specific matters were submitted to a vote of AIM ImmunoTech's security holders?
The filing states that the report is pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and reports on 'Submission of Matters to a Vote of Security Holders,' but the specific details of the vote are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 17, 2024.
What is the primary business of AIM ImmunoTech Inc. according to the filing?
AIM ImmunoTech Inc. is involved in 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Where are AIM ImmunoTech Inc.'s principal executive offices located?
The principal executive offices are located at 2117 SW Highway 484, Ocala, FL 34473.
Has AIM ImmunoTech Inc. operated under any former names?
Yes, the company was formerly known as HEMISPHERX BIOPHARMA INC, with a date of name change on June 14, 1995.
Filing Stats: 724 words · 3 min read · ~2 pages · Grade level 9.6 · Accepted 2024-12-20 17:00:31
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Indic
Filing Documents
- form8-k.htm (8-K) — 48KB
- 0001493152-24-051088.txt ( ) — 219KB
- aim-20241217.xsd (EX-101.SCH) — 3KB
- aim-20241217_lab.xml (EX-101.LAB) — 33KB
- aim-20241217_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM ImmunoTech Inc. Date: December 20, 2024 By: /s/ Thomas K. Equels Thomas K. Equels, CEO